The FLAURA trial established osimertinib as a first-line therapy for EGFR-mutant advanced NSCLC [24,38,39,40,41,42,43], revealing significant improvements in PFS (18.9 vs. 10.2 months) and OS (38.6 vs. 31.8 months) compared to first-generation TKIs (gefitinib/erlotinib) [24]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.